Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2007 1
2009 2
2010 3
2011 2
2012 3
2014 2
2015 2
2016 2
2017 4
2018 8
2019 8
2020 15
2021 19
2022 12
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: olmedo me. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohé C, Farago AF, López-Vilariño JA, Cullell-Young M, Nieto A, Vasco N, Gómez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sánchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Dómine M, Paz-Ares L. Aix SP, et al. Among authors: olmedo me. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14. Lancet Respir Med. 2023. PMID: 36252599 Clinical Trial.
Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.
Garrido P, Olmedo ME, Gómez A, Paz Ares L, López-Ríos F, Rosa-Rosa JM, Palacios J. Garrido P, et al. Among authors: olmedo me. Ther Adv Med Oncol. 2017 Sep;9(9):589-597. doi: 10.1177/1758834017719829. Epub 2017 Jul 24. Ther Adv Med Oncol. 2017. PMID: 29081842 Free PMC article. Review.
Aging during C. elegans L1 quiescence.
Mata-Cabana A, Romero-Expósito FJ, Olmedo M. Mata-Cabana A, et al. Among authors: olmedo m. Aging (Albany NY). 2020 Sep 27;12(18):17756-17758. doi: 10.18632/aging.104027. Epub 2020 Sep 27. Aging (Albany NY). 2020. PMID: 32986012 Free PMC article. No abstract available.
Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria.
Pericàs JM, Llopis J, Muñoz P, González-Ramallo V, García-Leoni ME, de Alarcón A, Luque R, Fariñas MC, Goenaga MÁ, Hernández-Meneses M, Nicolás D, Ramos-Martínez A, Rodríguez-Esteban MÁ, Villoslada-Gelabert A, Miró JM; GAMES Investigators. Pericàs JM, et al. Open Forum Infect Dis. 2022 Aug 30;9(9):ofac442. doi: 10.1093/ofid/ofac442. eCollection 2022 Sep. Open Forum Infect Dis. 2022. PMID: 36172059 Free PMC article.
Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci.
Escrihuela-Vidal F, Berbel D, Fernández-Hidalgo N, Escolà-Vergé L, Muñoz P, Olmedo M, Goenaga MÁ, Goikoetxea J, Fariñas MC, De Alarcón A, Miró JM, Ojeda G, Plata A, Cuervo G, Carratalà J; GAMES Investigators. Escrihuela-Vidal F, et al. Among authors: olmedo m. Clin Infect Dis. 2023 Nov 11;77(9):1273-1281. doi: 10.1093/cid/ciad375. Clin Infect Dis. 2023. PMID: 37345869
Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial.
Páez-Vega A, Gutiérrez-Gutiérrez B, Agüera ML, Facundo C, Redondo-Pachón D, Suñer M, López-Oliva MO, Yuste JR, Montejo M, Galeano-Álvarez C, Ruiz-San Millan JC, Los-Arcos I, Hernández D, Fernández-Ruiz M, Muñoz P, Valle-Arroyo J, Cano A, Rodríguez-Benot A, Crespo M, Rodelo-Haad C, Lobo-Acosta MA, Garrido-Gracia JC, Vidal E, Guirado L, Cantisán S, Torre-Cisneros J; TIMOVAL Study Group. Páez-Vega A, et al. Clin Infect Dis. 2022 Mar 9;74(5):757-765. doi: 10.1093/cid/ciab574. Clin Infect Dis. 2022. PMID: 34228099 Free article. Clinical Trial.
Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
Herrera-Hidalgo L, Muñoz P, Álvarez-Uría A, Alonso-Menchén D, Luque-Marquez R, Gutiérrez-Carretero E, Fariñas MDC, Miró JM, Goenaga MA, López-Cortés LE, Angulo-Lara B, Boix-Palop L, de Alarcón A; Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) Cohort Investigators. Herrera-Hidalgo L, et al. Int J Infect Dis. 2023 Dec;137:134-143. doi: 10.1016/j.ijid.2023.10.019. Epub 2023 Nov 4. Int J Infect Dis. 2023. PMID: 37926195 Free article.
86 results